Literature DB >> 27183585

Impaired P2X1 Receptor-Mediated Adhesion in Eosinophils from Asthmatic Patients.

Adam Wright1, Martyn Mahaut-Smith2, Fiona Symon3, Nicolas Sylvius4, Shaun Ran3, Mona Bafadhel5, Michelle Muessel3, Peter Bradding3, Andrew Wardlaw3, Catherine Vial6.   

Abstract

Eosinophils play an important role in the pathogenesis of asthma and can be activated by extracellular nucleotides released following cell damage or inflammation. For example, increased ATP concentrations were reported in bronchoalveolar lavage fluids of asthmatic patients. Although eosinophils are known to express several subtypes of P2 receptors for extracellular nucleotides, their function and contribution to asthma remain unclear. In this article, we show that transcripts for P2X1, P2X4, and P2X5 receptors were expressed in healthy and asthmatic eosinophils. The P2X receptor agonist α,β-methylene ATP (α,β-meATP; 10 μM) evoked rapidly activating and desensitizing inward currents (peak 18 ± 3 pA/pF at -60 mV) in healthy eosinophils, typical of P2X1 homomeric receptors, which were abolished by the selective P2X1 antagonist NF449 (1 μM) (3 ± 2 pA/pF). α,β-meATP-evoked currents were smaller in eosinophils from asthmatic patients (8 ± 2 versus 27 ± 5 pA/pF for healthy) but were enhanced following treatment with a high concentration of the nucleotidase apyrase (17 ± 5 pA/pF for 10 IU/ml and 11 ± 3 pA/pF for 0.32 IU/ml), indicating that the channels are partially desensitized by extracellular nucleotides. α,β-meATP (10 μM) increased the expression of CD11b activated form in eosinophils from healthy, but not asthmatic, donors (143 ± 21% and 108 ± 11% of control response, respectively). Furthermore, α,β-meATP increased healthy (18 ± 2% compared with control 10 ± 1%) but not asthmatic (13 ± 1% versus 10 ± 0% for control) eosinophil adhesion. Healthy human eosinophils express functional P2X1 receptors whose activation leads to eosinophil αMβ2 integrin-dependent adhesion. P2X1 responses are constitutively reduced in asthmatic compared with healthy eosinophils, probably as the result of an increase in extracellular nucleotide concentration.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27183585     DOI: 10.4049/jimmunol.1501585

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  Evidence for shear-mediated Ca2+ entry through mechanosensitive cation channels in human platelets and a megakaryocytic cell line.

Authors:  Zeki Ilkan; Joy R Wright; Alison H Goodall; Jonathan M Gibbins; Chris I Jones; Martyn P Mahaut-Smith
Journal:  J Biol Chem       Date:  2017-04-17       Impact factor: 5.157

4.  Human group 2 innate lymphoid cells do not express the IL-5 receptor.

Authors:  Adam K A Wright; Cathryn Weston; Batika M J Rana; Christopher E Brightling; David J Cousins
Journal:  J Allergy Clin Immunol       Date:  2017-05-10       Impact factor: 10.793

5.  Development of a P2X1-eYFP receptor knock-in mouse to track receptors in real time.

Authors:  Martyn P Mahaut Smith; Richard J Evans; Catherine Vial
Journal:  Purinergic Signal       Date:  2019-07-08       Impact factor: 3.765

Review 6.  Purinergic Receptors in the Airways: Potential Therapeutic Targets for Asthma?

Authors:  Rebecca J Thompson; Ian Sayers; Katja Kuokkanen; Ian P Hall
Journal:  Front Allergy       Date:  2021-05-31

Review 7.  Eosinophils and Purinergic Signaling in Health and Disease.

Authors:  Davide Ferrari; Marta Vuerich; Fabio Casciano; Maria Serena Longhi; Elisabetta Melloni; Paola Secchiero; Andreas Zech; Simon C Robson; Tobias Müller; Marco Idzko
Journal:  Front Immunol       Date:  2020-07-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.